A real-world study of Trifluridine/Tipiracil (TAS-102) combined with bevacizumab as the late-line treatment of metastatic colorectal cancer

Abstract Background Trifluridine/Tipiracil (TAS-102) is an effective agent for the late-line treatment of metastatic colorectal cancer (mCRC). Combining TAS-102 with bevacizumab improves outcomes but may increase adverse events. We conducted a real-world, retrospective, exploratory comparison of two...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Shaocheng Zeng, Huangying Deng, Hanzhi Dong, Chunye Huang, Ruiwen Ruan, Xiaofeng Dai, Jianping Xiong, Jun Deng, Yangyang Yao
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Springer 2026-02-01
Sarja:	Discover Oncology
Aiheet:	Trifluridine/Tipiracil Bevacizumab Metastatic colorectal cancer Prognostic analysis
Linkit:	https://doi.org/10.1007/s12672-026-04459-6
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!